Guidelines on Muscle-invasive and Metastatic Bladder Cancer

The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

John E. Ware, Cathy D. Sherbourne · PubMed · 1992 · 34K citations

Pharmacy, Health Sciences, Geriatric Assessment +16

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations

Pharmacy, Oncology, Cancer Symptom Management +15

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

David Cella, David S. Tulsky, Geoffrey V. Gray et al. · Journal of Clinical Oncology · 1993 · 6K citations

Pharmacy, Oncology, Cancer Symptom Management +15

Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

Hans von der Maase, Lisa Sengeløv, J.T. Roberts et al. · Journal of Clinical Oncology · 2005 · 1.9K citations

Medicine, Oncology, Urology +6

Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology

Ahmad Shabsigh, Ruslan Korets, Kinjal Vora et al. · European Urology · 2008 · 1.4K citations

Medicine, Surgery, Urology +12